Hims & Hers Health (HIMS) presents a compelling investment setup with strong revenue growth and subscriber expansion, despite significant stock price declines and regulatory risks, suggesting a potential undervaluation and multi-year hold opportunity.
Source Post
Is Hims & Hers Health Inc HIMS A Good Time To Buy Now? HIMS Stock Analysis
Mar 15, 2026
The podcast analyzes Hims & Hers Health (HIMS), noting its significant revenue growth (59% YoY) and subscriber base increase (2.5M users) despite a 52% stock price decline year-to-date. The discussion highlights a fundamental tension between explosive business growth and a collapsing share price, exploring potential scenarios of market overreaction versus underlying business issues. Key concerns include shrinking gross margins and regulatory/legal risks related to compounded GLP-1 medications, countered by strong adjusted EBITDA growth, a solid balance sheet, strategic acquisitions like Eucalyptus for international expansion, and a pivot towards diversification beyond weight loss drugs. The analysis suggests the current stock price may have already priced in worst-case scenarios, presenting a potential undervaluation and a multi-year hold opportunity.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
HIMSbuy opened Mar 15, 2026
+18.37%